Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BY101921 in advanced solid tumors
NCT06433726Phase 1Recruiting
- Sponsor
- Baiyu Pharmaceutical
- Start
- Mar 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BY101921 in solid tumor, sponsored by Baiyu Pharmaceutical. Primary endpoints: Safety and Tolerability and Maximum Tolerated Dose. Started Mar 2024; status: recruiting.
02
Drugs
BY101921
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06433726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06433726.